Premium
Teduglutide for safe reduction of parenteral nutrition requirements in adults: a systematic review (1035.11)
Author(s) -
Naberhuis Jane,
Tappenden Kelly
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.1035.11
Subject(s) - medicine , parenteral nutrition , medline , adverse effect , intensive care medicine , cochrane library , clinical trial , placebo , randomized controlled trial , pediatrics , alternative medicine , pathology , political science , law
Teduglutide, a recombinant analogue of human glucagon‐like peptide‐2, is the first long‐term medical therapy approved for the treatment of adults dependent on parenteral nutrition (PN). The aim of this systematic review was to assess the safety and efficacy of teduglutide in reducing parenteral nutrient or fluid requirements in PN‐dependent adults. Studies were identified using predefined search criteria and multiple databases, including Medline and Embase. The search was completed to October 13, 2013 in the absence of date or study design restrictions. Hits were assessed for inclusion criteria and methodological quality by two independent reviewers using risk of bias assessment tables adapted from the Cochrane Collaboration. The outcomes of interest were changes in parenteral nutrient or fluid requirements (weekly volume and/or infusion days) and adverse event data. From 1,214 unique hits, 58 abstracts were reviewed. Thirty‐five reports met the inclusion criteria, including data from two phase III, placebo‐controlled clinical trials and their respective extension studies. Data provided will assess the evidence base for provision of teduglutide in adult patients dependent on PN.